Trial Profile

A phase III study of controlled-release metadoxine in children with attention-deficit hyperactivity disorder (ADHD).

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 28 Nov 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metadoxine (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Registrational; Therapeutic Use

Most Recent Events

15 Nov 2017 According to an Arcturus Therapeutics media release, Alcobra merged with Arcturus Therapeutics and the combined company is named as Arcturus Therapeutics
30 Aug 2016 According to Alcobra media release, this study is expected to start in the fourth quarter of 2016.
06 Aug 2013 This trial is expected to start later in 2013, according to an Alcobra media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com